Regeneron Pharmaceuticals 8-K
NegativeEarningsImpairment / charge
Upfront and opt-in payments under collaboration and licensing deals drive an expected ≈$127M pre-tax acquired IPR&D charge.
Filed 2026-07-06 07:00 ET
- 2.02 Results of Operations
Summary
Regeneron disclosed an expected acquired in-process research and development charge for Q2 2026. The charge relates to upfront and opt-in payments under collaboration and licensing agreements; Q2 results are not finalized.
Key Figures
- Expected Q2 2026 acquired IPR&D charge: ≈$127M pre-tax; expected to reduce both GAAP and non-GAAP diluted EPS by ≈$1.00.
Investor Takeaways
- Watch for the finalized Q2 results to confirm the charge and its EPS impact.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3